Effect of Plasmapheresis on the Efficacy of Rituximab in Antibody-Mediated Rejection Patients.
Transplant Proc
; 56(3): 723-725, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38383260
ABSTRACT
BACKGROUND:
Rituximab and plasmapheresis (PP) suppress and eliminate antibody production in patients experiencing antibody-mediated rejection (AMR). Herein, we discuss a case where rituximab was less effective after PP for treating AMR. CASE A 55-year-old male patient underwent kidney transplantation. His renal function remained normal for 1 year. Subsequently, renal function declined, and (donor-specific antibodies showed positive results. A biopsy of the transplanted kidney revealed AMR. On the day of the biopsy, the medical staff administered 200 mg of rituximab, followed by IV immunoglobulin (IVIg) and PP the next day. The time interval between PP + IVIg treatment and rituximab was 12 h. As a result, the B-cell markers CD19 and CD20 did not decrease sufficiently, and the patient's creatinine and glomerular filtration rate muscles did not recover adequately.CONCLUSION:
We report a case in which PP was administered shortly after rituximab injection, resulting in insufficient B-cell inhibition due to the removal of rituximab.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
Problema de salud:
1_recursos_humanos_saude
Asunto principal:
Trasplante de Riñón
/
Plasmaféresis
/
Rituximab
/
Rechazo de Injerto
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Transplant Proc
Año:
2024
Tipo del documento:
Article
País de afiliación:
Corea del Sur